5.250USD+6.71%Mkt Cap: 123.80M USDP/E: —Last update: 2026-05-26
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular end…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap123.80M USD
Enterprise Value24.25M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-43.44M USD
Revenue/Share—
Last Price5.250 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.24
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.49
EPS (TTM)-0.78
EPS (Forward)-1.58
52W Range
2.14032% of range11.88
52W High11.88 USD
52W Low2.140 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.11%
ROA-35.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.37M USD
CapEx (TTM)200.00K USD
FCF Margin—
FCF Yield—
Net Debt-97.22M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio12.19
Quick Ratio12.03
Book Value/Sh3.441 USD
Cash/Share4.098 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:23
Split DateJan 16, 2025
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)18.75 USD
Target Range7.000 USD – 25.00 USD
# Analysts8
Ownership
Shares Out.23.79M
Float6.57M
Insiders9.90%
Institutions78.36%
Short Interest
Short Ratio9.2d
Short % Float10.71%
Short % Out.3.50%
Shares Short805.75K
Short (prev mo.)995.27K
Technical
SMA 506.016 (-12.7%)
SMA 2006.505 (-19.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)96.35K
Avg Vol (10d)87.81K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—